Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment

NCT03672240 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

6

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Muscle Invasive Bladder Cancer (NMIBC)

Interventions

DRUG: APL-1202

Sponsor

Asieris Pharmaceutical Technologies Co., Ltd.